Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Synaptic vesicle protein 2A(SV2A) is the specific binding site of the anti‐epileptic drug levetiracetam (LEV) and its higher affinity analogue UCB30889. Moreover, the protein has been well validated as a target for anticonvulsant therapy. Here, we report the identification of UCB1244283 acting as a SV2A positive allosteric modulator of UCB30889. Experimental Approach: UCB1244283 was characterized in vitro using radioligand binding assays with[3 H]UCB30889 on recombinant SV2A expressed in HEK cells and on rat cortex.In vivo, the compound was tested in sound‐sensitive mice. Key Results: Saturation binding experiments in the presence of UCB1244283 demonstrated a fivefold increase in the affinity of[3 H]UCB30889 for human recombinant SV2A, combined with a twofold increase of the total number of binding sites. Similar results were obtained on rat cortex. In competition binding experiments,UCB1244283 potentiated the affinity of UCB30889 while the affinity of LEV remained unchanged.UCB1244283 significantly slowed down both the association and dissociation kinetics of[3 H]UCB30889. Following i.c.v. administration in sound‐sensitive mice,UCB1244283 showed a clear protective effect against both tonic and clonic convulsions. Conclusions and Implications: These results indicate that UCB1244283 can modulate the conformation of SV2A, thereby inducing a higher affinity state for UCB30889. Our results also suggest that the conformation of SV2A per se might be an important determinant of its functioning, especially during epileptic seizures. Therefore, agents that act on the conformation of SV2A might hold great potential in the search for new SV2A‐based anticonvulsant therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 7×
“The SV2A protein has been demonstrated to be the binding site of LEV (Lynch et al., 2004) and to mediate its anticonvulsant activity in vivo (Kaminski et al.”
BackgroundMethodInfluentialGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 2×
“…Journal of Pharmacology © 2013 The British Pharmacological Society SV2A -/- knockout mice are characterized by a lethal seizure phenotype without any obvious abnormalities in synaptic vesicle biogenesis, supporting an important role of the protein in synaptic transmission (Crowder et al., 1999).”
BackgroundSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
SV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212
SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176 · cited 3×
“…2008), peptides, sugars, lipids etc., post-translational modifications [phosphorylation (Gross et al., 1995), glycosylation (Dong et al., 2008; Chang and Sudhof, 2009), etc.] or dimerization which has been reported for several other members of the MFS (Geertsma et al., 2005; Tanabe et al.,…”
BackgroundCotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · cited 2×
“Although, the exact function of SV2A in this process is not known, current evidence points towards an involvement of the protein in calcium-dependent exocytosis (Xu and Bajjalieh, 2001; Nowack et al., 2010; Wan et al., 2010; Yao et al., 2010), but also neurotransmitter loading/retention in synaptic vesicles (Budzinski…”
BackgroundGillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Self-citationSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138 · cited 2×
“Although, the exact function of SV2A in this process is not known, current evidence points towards an involvement of the protein in calcium-dependent exocytosis (Xu and Bajjalieh, 2001; Nowack et al., 2010; Wan et al., 2010; Yao et al., 2010), but also neurotransmitter loading/retention in synaptic vesicles (Budzinski…”
Background
Cited by
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
“that ligand binding to SV2A would promote/stabilize a conformation that enables the protein to fulfill a role in providing seizure protection [88].”
BackgroundInfluentialSelf-citationKlitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Self-citationLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“multiple interacting binding sites [91].”
BackgroundInfluentialA review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“While the anticonvulsant effect of BRV or LEV binding to SV2A is not fully understood, one hypothesis is that ligand binding to SV2A may stabilize a certain conformation of the protein, resulting in a potentiation or optimization of its function, thereby providing seizure protection.(39) Rat hippocampal slice research…”
BackgroundVogl, C., Tanifuji, S., Danis, B., Daniels, V., Foerch, P., Wolff, C., Whalley, B. J., Mochida, S., & Stephens, G. J. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12799 · Cited by 35
“Furthermore, the recombinant SV2A expressed in HEK cells was shown to retain the pharmacology towards small molecule ligands, indicating that the SV2A protein is correctly processed and folded in this cell system (Gillard et al., 2006; Daniels et al., 2013).”
Background
Metadata
- Authors
- Daniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-06-12
- Volume
- 169
- Issue
- 5
- Pages
- 1091-1101
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1505043869
- Cited by
- 28
- References
- 10
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. https://app.cochat.ai/papers/10.1111/bph.12192
- The paper
- Daniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M. (2013). Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. British Journal of Pharmacology. https://doi.org/10.1111/bph.12192
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.